Pfizer announced its experimental lung cancer drug sigvotatug vedotin failed to improve survival in advanced lung cancer patients, dealing a setback to the drug.
bloomberg-industries06/23, 03:37 AM
Related assets
Coming up for PFE
Explore next
Latest PFE news
Jin1008/04, 08:22 PM
LiveSquawk08/04, 06:11 PM
ZeroHedge08/04, 05:45 PM
Pfizer raises full-year revenue guidance to $60.5B–$62.5B from prior $59.5B–$62.5B.